Skip to main content

Table 2 Association of tumor GFRα1, GFRα3 and SDC3 mRNA expression with clinicopathologic parameters of patients with mammary carcinoma

From: Prognostic significance of the expression of GFRα1, GFRα3 and Syndecan-3, proteins binding ARTEMIN, in mammary carcinoma

  GFRα1 expression (n (%)) GFRα3 expression (n (%)) SDC3 expression (n (%))
Parameter n mRNA P mRNA P mRNA P
Age (years)
≤ 35 16 14 (87.5) 0.005 11 (68.8) 0.043 8 (50.0) 0.399
35-55 92 45 (48.9)   40 (43.5)   33 (35.9)  
> 55 51 21 (41.2)   17 (33.3)   16 (31.4)  
Tumor size (cm)
≤ 2 13 6(46.2) 0.62 4 (30.8) 0.406 7 (53.8) 0.364
2 ~ 5 115 56 (48.7)   48 (417)   39 (33.9)  
> 5 31 18 (58.1)   16 (51.6)   11 (35.5)  
Histologic type
Ductal 150 78(52.0) 0.142 67(44.7) 0.127 54(36.0) 0.333
Lobular 6 2(33.3)   1(16.7)   1(16.7)  
Mucinous 3 0(0)   0(0)   2(66.7)  
Lymph node metastasis
0 55 20 (36.4) 0.013 19 (34.5) 0.235 23 (41.8) 0.481
1 ~ 3 55 28 (50.9)   24(43.6)   17 (30.9)  
>3 49 32 (65.3)   25 (51.0)   17 (34.7)  
Grade
I 13 8 (61.5) 0.436 6 (46.2) 0.678 7 (53.8) 0.124
II 102 53 (52.0)   41 (40.2)   31 (30.4)  
III 44 19 (43.2)   21 (47.7)   19 (43.2)  
Stage
I-II 85 32 (37.6) 0.001 32 (37.6) 0.162 31 (36.5) 0.861
III-IV 74 48 (64.9)   36(48.6)   26 (35.1)  
ER status ^
- 94 49 (52.1) 0.582 37 (39.4) 0.297 31 (33.0) 0.364
+ 65 31 (47.7)   31 (47.7)   26 (40.0)  
PR status ^^
- 90 44 (48.9) 0.681 36 (40.0) 0.421 27 (30.0) 0.079
+ 69 36 (52.2)   32 (46.4)   30 (43.5)  
HER-2 *
- 121 53 (43.8) 0.003 47 (38.8) 0.074 44 (36.4) 0.809
+ 38 27 (71.1)   21 (55.3)   13 (34.2)  
  1. ^ ER positive required at least 10% staining nuclei.
  2. ^^ PR positive required at least 10% staining nuclei.
  3. HER-2 positive were 3+ or 2+ and FISH confirmed.
  4. Values in bold are significant (P < 0.05).